A tetracationic porphyrin with dual anti-prion activity

[1]  M. Kozak,et al.  Zn(II) binding causes interdomain changes in the structure and flexibility of the human prion protein , 2021, Scientific Reports.

[2]  S. Hornemann,et al.  Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies , 2021, Science advances.

[3]  M. Sallese,et al.  Activation of Src family kinase ameliorates secretory trafficking in mutant prion protein cells , 2021, The Journal of biological chemistry.

[4]  M. Woodside,et al.  Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone , 2021, Proceedings of the National Academy of Sciences.

[5]  S. Supattapone,et al.  Emergence of prions selectively resistant to combination drug therapy , 2020, PLoS pathogens.

[6]  S. Schreiber,et al.  Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints , 2020, bioRxiv.

[7]  G. Legname,et al.  Deciphering Copper Coordination in the Mammalian Prion Protein Amyloidogenic Domain. , 2020, Biophysical journal.

[8]  A. Dalle Vedove,et al.  Identification of compounds inhibiting prion replication and toxicity by removing PrPC from the cell surface , 2020, Journal of neurochemistry.

[9]  M. Frosch,et al.  PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins , 2019, Acta Neuropathologica.

[10]  M. D. Di Bari,et al.  Development of a new largely scalable in vitro prion propagation method for the production of infectious recombinant prions for high resolution structural studies , 2019, PLoS pathogens.

[11]  S. Schreiber,et al.  Antisense oligonucleotides extend survival of prion-infected mice , 2019, JCI insight.

[12]  G. Millhauser,et al.  Molecular Features of the Zn2+ Binding Site in the Prion Protein Probed by 113Cd NMR. , 2019, Biophysical journal.

[13]  Y. Matsuyama,et al.  A designer molecular chaperone against transmissible spongiform encephalopathy slows disease progression in mice and macaques , 2019, Nature Biomedical Engineering.

[14]  A. Saponaro.  Isothermal Titration Calorimetry: A Biophysical Method to Characterize the Interaction between Label-free Biomolecules in Solution. , 2018, Bio-protocol.

[15]  A. Corti,et al.  Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation. , 2018, Journal of medicinal chemistry.

[16]  M. D. Di Bari,et al.  Cofactors influence the biological properties of infectious recombinant prions , 2018, Acta Neuropathologica.

[17]  J. Castilla,et al.  Generation of a new infectious recombinant prion: a model to understand Gerstmann–Sträussler–Scheinker syndrome , 2017, Scientific Reports.

[18]  H. Anderson,et al.  Nanorings with copper(ii) and zinc(ii) centers: forcing copper porphyrins to bind axial ligands in heterometallated oligomers† †Electronic supplementary information (ESI) available: Synthesis and characterization of new compounds, UV-vis-NIR titrations and binding data for reference compounds and fo , 2016, Chemical science.

[19]  S. Prusiner,et al.  Towards authentic transgenic mouse models of heritable PrP prion diseases , 2016, Acta Neuropathologica.

[20]  C. Brautigam,et al.  Integration and global analysis of isothermal titration calorimetry data for studying macromolecular interactions , 2016, Nature Protocols.

[21]  R. Nonno,et al.  A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein , 2016, Scientific Reports.

[22]  Patrick F. Sullivan,et al.  Quantifying prion disease penetrance using large population control cohorts , 2016, Science Translational Medicine.

[23]  R. Chiesa.  The Elusive Role of the Prion Protein and the Mechanism of Toxicity in Prion Disease , 2015, PLoS pathogens.

[24]  G. Forloni,et al.  Transgenic Fatal Familial Insomnia Mice Indicate Prion Infectivity-Independent Mechanisms of Pathogenesis and Phenotypic Expression of Disease , 2015, PLoS pathogens.

[25]  J. Lippincott-Schwartz,et al.  ER Stress-Induced Clearance of Misfolded GPI-Anchored Proteins via the Secretory Pathway , 2014, Cell.

[26]  S. Prusiner,et al.  Drug resistance confounding prion therapeutics , 2013, Proceedings of the National Academy of Sciences.

[27]  J. Steyaert,et al.  Recombinant Human Prion Protein Inhibits Prion Propagation in vitro , 2013, Scientific Reports.

[28]  C. Mueller-Dieckmann,et al.  Upgraded ESRF BM29 beamline for SAXS on macromolecules in solution , 2013, Journal of synchrotron radiation.

[29]  J. Pelton,et al.  Zinc drives a tertiary fold in the prion protein with familial disease mutation sites at the interface. , 2013, Structure.

[30]  I. Olsaker,et al.  Healthy goats naturally devoid of prion protein , 2012, Veterinary Research.

[31]  S. Prusiner,et al.  Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice , 2012, Molecular therapy. Nucleic acids.

[32]  D. Harris,et al.  The N-Terminal, Polybasic Region Is Critical for Prion Protein Neuroprotective Activity , 2011, PloS one.

[33]  A. Srivastava,et al.  Copper Alters Aggregation Behavior of Prion Protein and Induces Novel Interactions between Its N- and C-terminal Regions , 2011, The Journal of Biological Chemistry.

[34]  G. Forloni,et al.  Cell Type-Specific Neuroprotective Activity of Untranslocated Prion Protein , 2010, PloS one.

[35]  R. Chiesa,et al.  The hydrophobic core region governs mutant prion protein aggregation and intracellular retention. , 2010, The Biochemical journal.

[36]  J. Collinge,et al.  Pharmacological chaperone for the structured domain of human prion protein , 2010, Proceedings of the National Academy of Sciences.

[37]  R. Kascsak.  Reiterating the Epitope Specificity of Prion-specific mAb 3F4 , 2010, The Journal of Biological Chemistry.

[38]  Beat Meier,et al.  Prions , 2010 .

[39]  Frank Baumann,et al.  Axonal prion protein is required for peripheral myelin maintenance , 2010, Nature Neuroscience.

[40]  Charles Weissmann,et al.  Darwinian Evolution of Prions in Cell Culture , 2010, Science.

[41]  B. Caughey,et al.  Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan. , 2010, Journal of molecular biology.

[42]  D. Harris,et al.  Mutant Prion Protein Expression Is Associated with an Alteration of the Rab GDP Dissociation Inhibitor α (GDI)/Rab11 Pathway* , 2009, Molecular & Cellular Proteomics.

[43]  S. Prusiner,et al.  Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions , 2009, PLoS pathogens.

[44]  Philippe Pierre,et al.  SUnSET, a nonradioactive method to monitor protein synthesis , 2009, Nature Methods.

[45]  L. Ferrari,et al.  Mutant Prion Protein Expression Causes Motor and Memory Deficits and Abnormal Sleep Patterns in a Transgenic Mouse Model , 2008, Neuron.

[46]  J. Collinge,et al.  Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease , 2008, Proceedings of the National Academy of Sciences.

[47]  G. J. Raymond,et al.  Hemin Interactions and Alterations of the Subcellular Localization of Prion Protein* , 2007, Journal of Biological Chemistry.

[48]  B. Caughey,et al.  Cyclic Tetrapyrrole Sulfonation, Metals, and Oligomerization in Antiprion Activity , 2007, Antimicrobial Agents and Chemotherapy.

[49]  T. Wisniewski,et al.  CpG oligodeoxynucleotide‐enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie‐associated fibrils , 2007, Journal of leukocyte biology.

[50]  F. Cordelières,et al.  A guided tour into subcellular colocalization analysis in light microscopy , 2006, Journal of microscopy.

[51]  N. Greenfield.  Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions , 2006, Nature Protocols.

[52]  S. Banfi,et al.  Antibacterial activity of tetraaryl-porphyrin photosensitizers: an in vitro study on Gram negative and Gram positive bacteria. , 2006, Journal of photochemistry and photobiology. B, Biology.

[53]  B. Caughey,et al.  Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds? , 2006, Accounts of chemical research.

[54]  P. Gramatica,et al.  Comparison between 5,10,15,20-tetraaryl- and 5,15-diarylporphyrins as photosensitizers: synthesis, photodynamic activity, and quantitative structure-activity relationship modeling. , 2006, Journal of medicinal chemistry.

[55]  B. Caughey,et al.  A Porphyrin Increases Survival Time of Mice after Intracerebral Prion Infection , 2006, Antimicrobial Agents and Chemotherapy.

[56]  A. Hill,et al.  Detection of prion epitopes on PrPc and PrPsc of transmissible spongiform encephalopathies using specific monoclonal antibodies to PrP , 2005, Immunology and cell biology.

[57]  Wayne Boucher,et al.  The CCPN data model for NMR spectroscopy: Development of a software pipeline , 2005, Proteins.

[58]  R. S. Stewart,et al.  Cytosolic Prion Protein (PrP) Is Not Toxic in N2a Cells and Primary Neurons Expressing Pathogenic PrP Mutations* , 2005, Journal of Biological Chemistry.

[59]  T. James,et al.  NMR-based characterization of phenothiazines as a RNA binding scaffold. , 2004, Journal of the American Chemical Society.

[60]  Sebastian Brandner,et al.  Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis , 2003, Science.

[61]  D. Harris.  Trafficking, turnover and membrane topology of PrP. , 2003, British medical bulletin.

[62]  Shu-Hua Cheng,et al.  Substituent and axial ligand effects on the electrochemistry of zinc porphyrins , 2002 .

[63]  C. L. Coyle,et al.  EQUILIBRIA OF IMIDAZOLE WITH IRON(III) TETRAPHENYLPORPHINE , 2002 .

[64]  D. Harris,et al.  Nerve Growth Factor‐Induced Differentiation Does Not Alter the Biochemical Properties of a Mutant Prion Protein Expressed in PC12 Cells , 2000, Journal of neurochemistry.

[65]  W. Caughey,et al.  Porphyrin and phthalocyanine antiscrapie compounds. , 2000, Science.

[66]  K Wüthrich,et al.  NMR solution structure of the human prion protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  D. Harris,et al.  Successful Transmission of Three Mouse-Adapted Scrapie Strains to Murine Neuroblastoma Cell Lines Overexpressing Wild-Type Mouse Prion Protein , 2000, Journal of Virology.

[68]  C. Bostock,et al.  Characterization and polyanion-binding properties of purified recombinant prion protein. , 1999, The Biochemical journal.

[69]  B. Caughey,et al.  Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Westaway,et al.  The cellular prion protein binds copper in vivo , 1997, Nature.

[71]  S. Grzesiek,et al.  The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. , 1996, Biochemistry.

[72]  K. Moulder,et al.  The N-terminal Domain of a Glycolipid-anchored Prion Protein Is Essential for Its Endocytosis via Clathrin-coated Pits (*) , 1995, The Journal of Biological Chemistry.

[73]  A. Aguzzi,et al.  High Prion and PrPSc Levels but Delayed Onset of Disease in Scrapie-Inoculated Mice Heterozygous for a Disrupted PrP Gene , 1994, Molecular medicine.

[74]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.

[75]  Ad Bax,et al.  Methodological advances in protein NMR , 1993 .

[76]  G. J. Raymond,et al.  Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells , 1993, Journal of virology.

[77]  S. Prusiner,et al.  Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein , 1992, Nature.

[78]  B. Ehlers,et al.  Chemoprophylaxis of scrapie in mice. , 1991, The Journal of general virology.

[79]  J. Heuser,et al.  Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation , 1989, The Journal of cell biology.

[80]  H. Wiśniewski,et al.  Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins , 1987, Journal of virology.

[81]  G. Millhauser,et al.  Molecular Features of the Zn 2 D Binding Site in the Prion Protein Probed by 113 Cd NMR , 2019 .

[82]  W. Surewicz,et al.  Prion protein and its conformational conversion: a structural perspective. , 2011, Topics in current chemistry.

[83]  A. Aguzzi,et al.  The prion organotypic slice culture assay—POSCA , 2008, Nature Protocols.

[84]  J. Castilla,et al.  Production of cattle lacking prion protein , 2007, Nature Biotechnology.